Gigacloud Technology Inc vs Liquidia Corporation Common Stock — how do they compare? Gigacloud Technology Inc trades at $57.75 (market cap $2.06B), while Liquidia Corporation Common Stock trades at $33.94 (market cap $3.04B). The key difference: Liquidia Corporation Common Stock is the larger of the two by market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 20 Days and Liquidia Corporation Common Stock for 0 Days on average.
| GCT | LQDA | |
|---|---|---|
Market Cap | $2.06B | $3.04B |
Volume | 820,423 | 21,111,778 |
Sector | Technology | Health |
52-Week High | $57.75 | $91.03 |
52-Week Low | $25.46 | $22.02 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $2.19B | $2.94B |
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.03, down 1.23% with a bullish technical outlook from moving averages but bearish oscillators. The company shows strong fundamentals with consistent earnings beats, 10.65% net margin, and 32.34% ROE. Revenue grew to $1.29B in 2025 with positive cash flow of $120.10M. Recent news highlights institutional interest and European expansion driving growth.
The stock presents value with a 13.75 P/E ratio but faces technical overbought signals and insider selling. Analyst consensus is bullish with $32.50 price target, though current price exceeds this. Key risks include market volatility and execution challenges in international expansion.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →